藥明生物(02269.HK)2021年純利增長100.6%至33.885億元 綜合項目增長43.7%至480個
格隆匯3月22日丨藥明生物(02269.HK)公吿,2021年度,公司收益102.9億元人民幣,同比增長83.3%;期間毛利率為46.9%,上年同期為45.1%;公司擁有人應占純利33.885億元,同比增長100.6%;公司擁有人應占經調整純利33.16億元,同比增長92.6%。
綜合項目由去年同期的334個,增長43.7%至2021年12月31日的480個,其中包括447個非COVID綜合項目,充分展現即使扣除COVID-19項目貢獻,集團業務增長依然強勁。
臨牀前項目由去年同期的169個,增長58.6%至2021年12月31日的268個。早期(第I及II期)臨牀開發項目由去年同期的135個,增長26.7%至2021年12月31日的171個(119個I期項目及52個II期項目)。
後期(第III期)臨牀開發項目由去年同期的28個,增長14.3%至2021年12月31日的32個,為啟動更多商業化生產項目奠定堅實基礎。
集團在報吿期內新增七個商業化生產項目。集團成功將更多項目從IND前階段推進至IND後階段:於報吿期內,27個項目已由臨牀前開發階段進入早期臨牀開發階段。
此外,集團有效執行贏得分子策略,進一步將18個外部項目從全球其他CDMO轉至集團管線。
截至報吿期末,集團已經簽署九份疫苗合約,包括與全球疫苗巨頭之一訂立合作生產協議,初始期限為20年,合約總值超過30億美元。集團也賦能客户開發三種COVID-19疫苗抗擊疫情。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.